Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408004 | 0.85 | APOL1 (0.43) | APOL1CFTRHTR1AHTR1DHTR1B | |
| SCHEMBL1903598 | 0.83 | HTR1A (0.51) | HTR1AHTR1DHTR1B | |
| SCHEMBL1899834 | 0.83 | HTR1A (0.51) | HTR1AHTR1DHTR1B | |
| SCHEMBL1899835 | 0.83 | HTR1A (0.51) | HTR1AHTR1DHTR1B | |
| SCHEMBL7415604 | 0.83 | MTNR1A (0.42) | APOL1CFTRHTR1AHTR1DHTR1B | |
| SCHEMBL7408320 | 0.79 | HTR1A (0.46) | APOL1CFTRHTR1AHTR1DHTR1B | |
| SCHEMBL11344966 | 0.78 | APOL1 (0.38) | APOL1HTR1AHTR1DHTR1B | |
| SCHEMBL6527927 | 0.77 | DRD2 (0.43) | — | |
| SCHEMBL7413287 | 0.76 | APOL1 (0.37) | APOL1CFTRHTR1AHTR1DHTR1B | |
| SCHEMBL24408259 | 0.76 | MTNR1A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | APOL1 4489/4885PARP1 2520/4885BRD4 371/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | APOL1 4489/4885PARP1 2520/4885BRD4 371/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | APOL1 4489/4885PARP1 2520/4885BRD4 371/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | APOL1 4489/4885PARP1 2520/4885BRD4 371/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | APOL1 4489/4885PARP1 2520/4885BRD4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.